Open AccessComparison of hyperthermic intraperitoneal chemotherapy regimens for treatment of peritoneal-metastasized colorectal cancer
Author(s) -
Julia Spiegelberg,
Hannes Neeff,
Philipp Holzner,
Mira Runkel,
Stefan FichtnerFeigl,
Torben Glatz
Publication year - 2020
Publication title -
world journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v12.i8.903
Subject(s) - medicine , oxaliplatin , hyperthermic intraperitoneal chemotherapy , colorectal cancer , univariate analysis , surgery , oncology , chemotherapy , cancer , multivariate analysis , cytoreductive surgery , ovarian cancer
Cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) improves patient survival in colorectal cancer (CRC) with peritoneal carcinomatosis (PC). Commonly used cytotoxic agents include mitomycin C (MMC) and oxaliplatin. Studies have reported varying results, and the evidence for the choice of the HIPEC agent and uniform procedure protocols is limited.